MiniMed Group, Inc. - Common Stock (MMED)

MiniMed Group (NASDAQ:MMED) reported fiscal 2027 first-quarter revenue of $843 million, with organic revenue growth of 15.8%, as demand for its newer insulin-delivery and continuous glucose monitoring products supported growth in the United States and international markets. Chief Executive Officer

On Tuesday, Minimed Group (NASDAQ:MMED) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial

The medical device maker still has a bright future.

Medtronic could finally be on the cusp of a long-awaited turnaround.

Even the hottest AI stocks won't win forever. Diversification is the key to long-term wealth.

Medtronic is on track to reverse after a major market meltdown driven by fear. The upside potential is double-digit, not including the dividend.

MiniMed Group (NASDAQ:MMED) reported record fiscal 2026 revenue and outlined a slate of product launches it said will support faster growth in fiscal 2027, as management held the company’s first earnings call as a standalone public company following its March IPO. Chief Executive Officer Que Dallar

These three stocks are deeply unloved, giving them material upside, and they have great businesses.

Medtronic is closing in on Dividend King status, and its surgical robot is gaining traction.

As of April 3, 2026, Medtronic plc (NYSE: MDT) stands at a critical inflection point in its 77-year history. Once viewed as a lumbering healthcare conglomerate burdened by its own scale, the Dublin-based medical technology giant is currently navigating the final stages of a profound structural transformation. With the recent partial IPO of its diabetes [...]